The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
Open accessAbstract
Anaplastic thyroid cancer (ATC) is a rare malignancy. While external beam radiation therapy has improved locoregional control, the median survival of ∼ 4 months has not changed in more than half a century due to uncontrolled systemic metastases. The objective of this study was to review the literature in order to identify potential new strategies for treating this highly lethal cancer. PubMed searches were the principal source of articles reviewed. The molecular pathogenesis of ATC includes mutations in BRAF, RAS , catenin (cadherin-associated protein), beta 1, PIK3CA , TP53, AXIN1 , PTEN , and APC genes, and chromosomal abnormalities are common. Several microarray studies have identified genes and pathways preferentially affected, and dysregulated microRNA profiles differ from differentiated thyroid cancers. Numerous proteins involving transcription factors, signaling pathways, mitosis, proliferation, cell cycle, apoptosis, adhesion, migration, epigenetics, and protein degradation are affected. A variety of agents have been successful in controlling ATC cell growth both in vitro and in nude mice xenografts. While many of these new compounds are in cancer clinical trials, there are few studies being conducted in ATC. With the recent increased knowledge of the many critical genes and proteins affected in ATC, and the extensive array of targeted therapies being developed for cancer patients, there are new opportunities to design clinical trials based upon tumor molecular profiling and preclinical studies of potentially synergistic combinatorial novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Melillo, R. M., Castellone, M. D., Guarino, V., Falco, V. D., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhøffer, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22758 · Cited by 310
RetractedMelillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87345 · Cited by 306
RetractedFRA-1 expression in hyperplastic and neoplastic thyroid diseases.
Chiappetta, G., Tallini, G., Biasio, M. C. D., Pentimalli, F., de Nigris, F., Losito, S., Fedele, M., Battista, S., Verde, P., Santoro, M., et al. (2000) · PubMed · Cited by 52
RetractedRao, A. S., Kremenevskaja, N., von Wasielewski, R., Jakubcakova, V., Kant, S., Resch, J., & Brabant, G. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1381 · Cited by 37
RetractedJemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Biochemical and Biophysical Research Communications
(1960) · Nature · doi:10.1038/186124d0 · Cited by 6,700
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307323101 · Cited by 4,095
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
HOSKINS, R. G. (1953) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-13-4-473 · Cited by 3,780
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662
The Versatile Role of microRNA-30a in Human Cancer
Wang, C., Yang, X., Chen, Y., & Chen, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471111 · Cited by 3,409
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
MicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells
Chan, J. A., Krichevsky, A. M., & Kosik, K. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0137 · Cited by 2,557
Nasir, O. (2013) · Kidney and Blood Pressure Research · doi:10.1159/000350152 · Cited by 2,331
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Sultan, M., Schulz, M. H., Richard, H., Magen, A., Klingenhoff, A., Scherf, M., Seifert, M., Borodina, T., Soldatov, A., Parkhomchuk, D., et al. (2008) · Science · doi:10.1126/science.1160342 · Cited by 1,293
The role of microRNA genes in papillary thyroid carcinoma
He, H., Jazdzewski, K., Li, W., Liyanarachchi, S., Nagy, R., Volinia, S., Calin, G. A., Liu, C.-G., Franssila, K., Suster, S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509603102 · Cited by 1,215
Croce, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072367 · Cited by 1,055
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,042
Survivin, cancer networks and pathway-directed drug discovery
Altieri, D. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2293 · Cited by 994
Meng, F., Henson, R., Lang, M., Wehbe, H., Maheshwari, S., Mendell, J. T., Jiang, J., Schmittgen, T. D., & Patel, T. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.057 · Cited by 984
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.9.1382 · Cited by 877
Targeting polo-like kinase 1 for cancer therapy
Strebhardt, K., & Ullrich, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1841 · Cited by 841
PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid Carcinoma
Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C.-J., Mueller, E., Spiegelman, B. M., & Fletcher, J. A. (2000) · Science · doi:10.1126/science.289.5483.1357 · Cited by 784
Anaplastic thyroid carcinoma: Treatment outcome and prognostic factors
Kebebew, E., Greenspan, F. S., Clark, O. H., Woeber, K. A., & McMillan, A. (2005) · Cancer · doi:10.1002/cncr.20936 · Cited by 666
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S. H., & Koeffler, H. P. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116168 · Cited by 649
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 623
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Orlowski, R. Z., & Kuhn, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2218 · Cited by 578
Schweppe, R. E., Klopper, J. P., Korch, C., Pugazhenthi, U., Benezra, M., Knauf, J. A., Fagin, J. A., Marlow, L. A., Copland, J. A., Smallridge, R. C., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1102 · Cited by 563
Self-citationClinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030305 · Cited by 533
MicroRNA deregulation in human thyroid papillary carcinomas
Pallante, P., Visone, R., Ferracin, M., Ferraro, A., Berlingieri, M. T., Troncone, G., Chiappetta, G., Liu, C. G., Santoro, M., Negrini, M., et al. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01209 · Cited by 527
Journal of Cancer Research and Clinical Oncology
(2021) · Forum · doi:10.1007/s12312-021-00982-5 · Cited by 512
The American journal of surgical pathology
Wilkins, L. W. (1977) · Cited by 501
Anaplastic thyroid carcinoma: A 50-year experience at a single institution
McIver, B., HAY, I. D., Giuffrida, D., et al. (2001) · Surgery · doi:10.1067/msy.2001.118266 · Cited by 484
Shimaoka, K., Schoenfeld, D. A., Dewys, W. D., Creech, R. H., & Deconti, R. (1985) · Cancer · doi:10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e · Cited by 464
Ryder, M., Ghossein, R. A., Ricarte-Filho, J. C. M., Knauf, J. A., & Fagin, J. A. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0036 · Cited by 443
Cancer Chemotherapy and Pharmacology
(2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/280.1432-0843 · Cited by 430
Hou, P., Liu, D., Shan, Y., Hu, S., Studeman, K., Condouris, S., Wang, Y., Trink, A., El-Naggar, A. K., Tallini, G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1125 · Cited by 418
Visone, R., Russo, L., Pallante, P., De Martino, I., Ferraro, A., Leone, V., Borbone, E., Petrocca, F., Alder, H., Croce, C. M., et al. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0129 · Cited by 417
Dowlati, A., Robertson, K., Cooney, M. M., Petros, W. P., Stratford, M. R. L., Jesberger, J. A., Rafie, N., Overmoyer, B. A., Makkar, V., Stambler, B. S., et al. (2002) · PubMed · Cited by 403
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas
Visone, R., Pallante, P., Vecchione, A., Cirombella, R., Ferracin, M., Ferraro, A., Volinia, S., Coluzzi, S., Leone, V, Borbone, E., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210564 · Cited by 391
Liu, Z., Hou, P., Ji, M., Guan, H., Studeman, K., Jensen, K., Vasko, V., El-Naggar, A. K., & Xing, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0273 · Cited by 390
Aurora Kinases as Anticancer Drug Targets
Gautschi, O., Heighway, J., Mack, P. C., Purnell, P. R., Lara, P. N., & Gandara, D. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2179 · Cited by 386
Giordano, T. J., Kuick, R., Thomas, D. G., Misek, D. E., Vinco, M., Sanders, D., Zhu, Z., Ciampi, R., Roh, M., Shedden, K., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208822 · Cited by 383
Donghi, R., Longoni, A., Pilotti, S., Michieli, P., Della Porta, G., & Pierotti, M. A. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116385 · Cited by 370
ras Mutations Are Associated With Aggressive Tumor Phenotypes and Poor Prognosis in Thyroid Cancer
Garcia-Rostan, G., Zhao, H., Camp, R. L., Pollan, M., Herrero, A., Pardo, J., Wu, R., Carcangiu, M. L., Costa, J., & Tallini, G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.130 · Cited by 368
MicroRNAs modulate the chemosensitivity of tumor cells
Blower, P. E., Chung, J.-H., Verducci, J. S., Lin, S., Park, J.-K., Dai, Z., Liu, C.-G., Schmittgen, T. D., Reinhold, W. C., Croce, C. M., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0573 · Cited by 364
Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer
García-Rostán, G., Costa, A. M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M. J. A., Herrero, A., Fusco, A., Cameselle-Teijeiro, J., & Santoro, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4259 · Cited by 338
European Journal of Surgical Oncology
Winters, Z., Balta, V., Afzal, M., Llewellyn-Bennett, R., Rayter, Z., Cook, J. C., Greenwood, R., & King, M. T. (2015) · Cited by 314
Griffith, O. L., Melck, A., Jones, S. J. M., & Wiseman, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7330 · Cited by 314
Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.
Garcia-Rostan, G., Tallini, G., Herrero, A., D'Aquila, T. G., Carcangiu, M. L., & Rimm, D. L. (1999) · PubMed · Cited by 308
Frequent mutation and nuclear localization of betacatenin in anaplastic thyroid carcinoma
Gineza, G. (1999) · Cancer Research · Cited by 303
BRAF mutations in papillary carcinomas of the thyroid
Fukushima, T., Suzuki, S., Mashiko, M., Ohtake, T., Endo, Y., Takebayashi, Y., Sekikawa, K., Hagiwara, K., & Takenoshita, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206739 · Cited by 297
Ain, K. B., Egorin, M. J., DeSimone, P. A., & Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group* (2000) · Thyroid · doi:10.1089/thy.2000.10.587 · Cited by 295
A Limited Set of Human MicroRNA Is Deregulated in Follicular Thyroid Carcinoma
Weber, F., Teresi, R. E., Broelsch, C. E., Frilling, A., & Eng, C. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0693 · Cited by 293
Haigh, P. I., Ituarte, P. H. G., Wu, H. S., Treseler, P. A., Posner, M. D., Quivey, J. M., Duh, Q. Y., & Clark, O. H. (2001) · Cancer · doi:10.1002/1097-0142(20010615)91:12<2335::aid-cncr1266>3.0.co;2-1 · Cited by 292
β-Catenin Dysregulation in Thyroid Neoplasms
Garcia-Rostan, G., Camp, R. L., Herrero, A., Carcangiu, M. L., Rimm, D. L., & Tallini, G. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64045-x · Cited by 277
Development of Farnesyl Transferase Inhibitors: A Review
Appels, N. M. G. M., Beijnen, J. H., & Schellens, J. H. M. (2005) · The Oncologist · doi:10.1634/theoncologist.10-8-565 · Cited by 272
Epigenetic Activation of Tumor Suppressor MicroRNAs in Human Cancer Cells
Saito, Y., & Jones, P. M. (2006) · Cell Cycle · doi:10.4161/cc.5.19.3340 · Cited by 270
Frattini, M., Ferrario, C., Bressan, P., Balestra, D., De Cecco, L., Mondellini, P., Bongarzone, I., Collini, P., Gariboldi, M., Pilotti, S., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207980 · Cited by 266
Apoptosis: target of cancer therapy.
Ferreira, C. G., Epping, M. T., Kruyt, F. A. E., & Giaccone, G. (2002) · PubMed · Cited by 265
Mitomo, S., Maesawa, C., Ogasawara, S., Iwaya, T., Shibazaki, M., Yashima‐Abo, A., Kotani, K., Oikawa, H., Sakurai, E., Izutsu, N., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00666.x · Cited by 259
Oncogenic role of miR‐17‐92 cluster in anaplastic thyroid cancer cells
Takakura, S., Mitsutake, N., Nakashima, M., Namba, H., Saenko, V. A., Rogounovitch, T. I., Nakazawa, Y., Hayashi, T., Ohtsuru, A., & Yamashita, S. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00800.x · Cited by 242
Anaplastic carcinoma of the thyroid: A 24‐year experience
Tan, R. K. L., Finley, R. K., Driscoll, D., Bakamjian, V. Y., Hicks, W. L., & Shedd, D. P. (1995) · Head & Neck · doi:10.1002/hed.2880170109 · Cited by 237
Tennvall, J., Lundell, G., Wahlberg, P., Bergenfelz, A., Grimelius, L., Åkerman, M., Hjelm Skog, A.-L., & Wallin, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600361 · Cited by 235
Nikiforov, Y. E. (2004) · Endocrine Pathology · doi:10.1385/ep:15:4:319 · Cited by 234
Chromosomal Abnormalities in Cancer
Fröhling, S., & Döhner, H. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0803109 · Cited by 229
Quiros, R. M., Ding, H. G., Gattuso, P., Prinz, R. A., & Xu, X. (2005) · Cancer · doi:10.1002/cncr.21073 · Cited by 223
De Crevoisier, R., Baudin, E., Bachelot, A., Leboulleux, S., Travagli, J.-P., Caillou, B., & Schlumberger, M. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.05.032 · Cited by 221
Iannetti, A., Pacifico, F., Acquaviva, R., Lavorgna, A., Crescenzi, E., Vascotto, C., Tell, G., Salzano, A. M., Scaloni, A., Vuttariello, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710846105 · Cited by 210
Santarpia, L., El-Naggar, A. K., Cote, G. J., Myers, J. N., & Sherman, S. I. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1076 · Cited by 208
COMPARATIVE GENOMIC HYBRIDIZATION
Pinkel, D., & Albertson, D. G. (2005) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162140 · Cited by 203
The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma
Pierie, J. P. E. N., Muzikansky, A., Gaz, R. D., Faquin, W. C., & Ott, M. J. (2002) · Annals of Surgical Oncology · doi:10.1245/aso.2002.9.1.57 · Cited by 195
Microtubule-Associated Proteins as Targets in Cancer Chemotherapy
Bhat, K. M. R., & Setaluri, V. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3040 · Cited by 189
A Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma
Salvatore, G., Nappi, T. C., Salerno, P., Jiang, Y., Garbi, C., Ugolini, C., Miccoli, P., Basolo, F., Castellone, M. D., Cirafici, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1887 · Cited by 182
Lam, K.-Y., Lo, C.-Y., Chan, K.-W., & Wan, K.-Y. (2000) · Annals of Surgery · doi:10.1097/00000658-200003000-00005 · Cited by 182
Genome-Wide Appraisal of Thyroid Cancer Progression
Wreesmann, V. B., Ghossein, R. A., Patel, S. G., Harris, C. P., Schnaser, E. A., Shaha, A. R., Tuttle, R. M., Shah, J. P., Rao, P. H., & Singh, B. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64433-1 · Cited by 178
Begum, S., Rosenbaum, E., Henrique, R., Cohen, Y., Sidransky, D., & Westra, W. H. (2004) · Modern Pathology · doi:10.1038/modpathol.3800198 · Cited by 175
Gene Methylation in Thyroid Tumorigenesis
Xing, M. (2007) · Endocrinology · doi:10.1210/en.2006-0927 · Cited by 174
Application of Array-Based Comparative Genomic Hybridization to Clinical Diagnostics
Bejjani, B. A., & Shaffer, L. G. (2006) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.060029 · Cited by 173
Wang, Y., Hou, P., Yu, H., Wang, W., Ji, M., Zhao, S., Yan, S., Sun, X., Liu, D., Shi, B., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2019 · Cited by 172
Schiff, B. A., McMurphy, A. B., Jasser, S. A., Younes, M. N., Doan, D., Yigitbasi, O. G., Kim, S., Zhou, G., Mandal, M., Bekele, B. N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0690 · Cited by 169
Sebolt-Leopold, J. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0333 · Cited by 167
Kitazono, M. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.7.3430 · Cited by 163
Scala, S., Portella, G., Fedele, M., Chiappetta, G., & Fusco, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.070029997 · Cited by 155
Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin, U., Gimm, O., Hoang‐Vu, C., Dralle, H., Pfeifer, G. P., & Dammann, R. (2002) · PubMed · Cited by 149
Wreesmann, V. B., Sieczka, E. M., Socci, N. D., Hezel, M. P., Belbin, T. J., Childs, G. J., Patel, S. G., Patel, K. N., Tallini, G., Prystowsky, M. B., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1460 · Cited by 143
Molecular Profiling Distinguishes Papillary Carcinoma from Benign Thyroid Nodules
Finley, D. J., Arora, N., Zhu, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031811 · Cited by 141
Hou, P., Ji, M., & Xing, M. (2008) · Cancer · doi:10.1002/cncr.23869 · Cited by 136
Copland, J. A., Marlow, L. A., Kurakata, S., Fujiwara, K., Wong, A., Kreinest, P. A., Williams, S. F., Haugen, B. R., Klopper, J. P., & Smallridge, R. C. (2005) · Oncogene · doi:10.1038/sj.onc.1209267 · Cited by 134
Self-citationCosta, Â. M., Herrero, A., Fresno, M., Heymann, J. J., Alvarez, J. A., Cameselle‐Teijeiro, J., & García‐Rostán, G. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03077.x · Cited by 129
Mitsiades, C. S., McMillin, D. W., Kotoula, V., Poulaki, V., McMullan, C. J., Negri, J. M., Fanourakis, G., Tseleni‐Balafouta, S., Ain, K. B., & Mitsiades, N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2472 · Cited by 128
Leboeuf, R., Baumgartner, J. E., Benezra, M., Malaguarnera, R., Solit, D. B., Pratilas, C. A., Rosen, N. X., Knauf, J. A., & Fagin, J. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2825 · Cited by 127
Tallini, G., García‐Rostán, G., Herrero, A., Zelterman, D. A., Viale, G., Bòsari, S., & Carcangiu, M. L. (1999) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199906000-00007 · Cited by 127
Soares, P., Trovisco, V., Rocha, A. S., Feij�o, T., Rebocho, A. P., Fonseca, E., de Castro, I. V., Cameselle‐Teijeiro, J., Cardoso-Oliveira, M., & Sobrinho-Sim�es, M. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-004-1018-0 · Cited by 124
Miettinen, M., & Franssila, K. (2000) · Human Pathology · doi:10.1053/hupa.2000.16667 · Cited by 124
Wiseman, S. M., Masoudi, H., Niblock, P. G., Turbin, D. A., Rajput, A. B., Hay, J. H., Bugis, S. P., Filipenko, D., Huntsman, D. D., & Gilks, C. B. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9178-6 · Cited by 123
Inazawa, J., Inoue, J., & Imoto, I. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02486.x · Cited by 122
Baldassarre, G., Belletti, B., Bruni, P., Boccia, A. S., Trapasso, F., Pentimalli, F., Barone, M. V., Chiappetta, G., Vento, M. T., Spiezia, S., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6443 · Cited by 122
Catalano, M. G., Fortunati, N., Pugliese, M., Poli, R., Bosco, O., Mastrocola, R., Aragno, M., & Boccuzzi, G. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06970 · Cited by 121
UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas
Pallante, P., Berlingieri, M. T., Troncone, G., Kruhøffer, M., Orntoft, T. F., Viglietto, G., Caleo, A., Migliaccio, I., Decaussin‐Petrucci, M., Santoro, M. M., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602721 · Cited by 120
Falco, V. D., Guarino, V., Avilla, E., Castellone, M. D., Salerno, P., Salvatore, G., Faviana, P., Basolo, F., Santoro, M. M., & Melillo, R. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0899 · Cited by 119
Focal Adhesion Kinase: Targeting Adhesion Signaling Pathways for Therapeutic Intervention
Parsons, J. T., Slack‐Davis, J. K., Tilghman, R. W., & Roberts, W. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2220 · Cited by 118
The Role of Cell Cycle Regulatory Protein, Cyclin D1, in the Progression of Thyroid Cancer
Wang, S., Lloyd, R. V., Hutzler, M., Safran, M., Patwardhan, N. A., & Khan, A. A. (2000) · Modern Pathology · doi:10.1038/modpathol.3880157 · Cited by 116
Expression, regulation and function of autotaxin in thyroid carcinomas
Kehlen, A., Englert, N., Seifert, A., Klonisch, T. C., Dralle, H., Langner, J., & Hoang‐Vu, C. (2004) · International Journal of Cancer · doi:10.1002/ijc.20022 · Cited by 112
Loss of the CBX7 Gene Expression Correlates with a Highly Malignant Phenotype in Thyroid Cancer
Pallante, P., Federico, A., Berlingieri, M. T., Bianco, M., Ferraro, A., Forzati, F., Iaccarino, A., Russo, M., Pierantoni, G. M., Leone, V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0695 · Cited by 112
Aiello, A., Pandini, G., Frasca, F., Conte, E., Murabito, A., Sacco, A., Genua, M., Vigneri, R., & Belfiore, A. (2006) · Endocrinology · doi:10.1210/en.2005-1610 · Cited by 106
Yu, W., Imoto, I., Inoue, J., Onda, M., Emi, M., & Inazawa, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209899 · Cited by 104
Schagdarsurengin, U., Gimm, O., Dralle, H., Hoang‐Vu, C., & Dammann, R. (2006) · Thyroid · doi:10.1089/thy.2006.16.633 · Cited by 101
Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy
Blansfield, J., Caragacianu, D. L., Alexander, H. R., Tangrea, M. A., Morita, S. Y., Lorang, D., Schafer, P. H., Muller, G. W., Stirling, D., Royal, R. E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1562 · Cited by 100
Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis
Ros, P., Rossi, D. L., Acebrón, Á., & Santisteban, P. (1999) · Biochimie · doi:10.1016/s0300-9084(99)80086-8 · Cited by 99
Hsp90: A Novel Target for the Disruption of Multiple Signaling Cascades
Bishop, S., Burlison, J. A., & Blagg, B. S. J. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907780809778 · Cited by 99
Tirrò, E., Consoli, M. L., Massimino, M., Manzella, L., Frasca, F., Sciacca, L., Vicari, L., Stassi, G., Messina, L., Messina, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3248 · Cited by 99
AKT in Thyroid Tumorigenesis and Progression
Shinohara, M., Chung, Y. J., Saji, M., & Ringel, M. D. (2006) · Endocrinology · doi:10.1210/en.2006-0937 · Cited by 97
Kato, Y., Ying, H., Zhao, L., Furuya, F., Araki, O., Willingham, M. C., & Cheng, S.-Y. (2005) · Oncogene · doi:10.1038/sj.onc.1209299 · Cited by 97
Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues
Ulisse, S., Delcros, J., Baldini, E., Toller, M., Curcio, F., Giacomelli, L., Prigent, C., Ambesi‐Impiombato, F. S., D’Armiento, M., & Arlot‐Bonnemains, Y. (2006) · International Journal of Cancer · doi:10.1002/ijc.21842 · Cited by 95
Montero‐Conde, C., Martín-Campos, J. M., Lerma, E., Giménez‐Pérez, G., Martínez‐Guitarte, J., Combalía, N., Montaner, D. A., Matías‐Guiu, X., Dopazo, J., de Leiva, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210792 · Cited by 90
Thyroid cell transformation requires the expression of the HMGA1 proteins
Berlingieri, M. T., Pierantoni, G. M., Giancotti, V., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205368 · Cited by 90
Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer
Younes, M. N., Kim, S., Yigitbasi, O. G., Mandal, M., Jasser, S. A., Yazici, Y. D., Schiff, B. A., El‐Naggar, A. K., Bekele, B. N., Mills, G. B., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0078 · Cited by 87
Immunohistochemical analysis of thyroid‐specific transcription factors in thyroid tumors
Zhang, P., Zuo, H., Nakamura, Y., Nakamura, M., Wakasa, T., & Kakudo, K. (2006) · Pathology International · doi:10.1111/j.1440-1827.2006.01959.x · Cited by 85
Catalano, M. G., Poli, R., Pugliese, M., Fortunati, N., & Boccuzzi, G. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0096 · Cited by 84
The Selective Tyrosine Kinase Inhibitor, STI571, Inhibits Growth of Anaplastic Thyroid Cancer Cells
Podtcheko, A., Ohtsuru, A., Tsuda, S., Namba, H., Saenko, V., Nakashima, M., Mitsutake, N., Kanda, S., Kurebayashi, J., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021230 · Cited by 82
p53 family proteins in thyroid cancer
Malaguarnera, R., Vella, V., Vigneri, R., & Frasca, F. (2007) · Endocrine Related Cancer · doi:10.1677/erc.1.01223 · Cited by 80
Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer
Santoro, M., & Carlomagno, F. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0073 · Cited by 79
p53 mutations in all stages of thyroid carcinomas
Zou, M., Shi, Y., & Farid, N. R. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.77.4.1054 · Cited by 75
Liu, D., & Xing, M. (2008) · Thyroid · doi:10.1089/thy.2007.0357 · Cited by 71
Alterations of p53 and Expression of WAF1/p21 in Human Thyroid Tumors
Zedenius, J., Larsson, C., Wallin, G., Bäckdahl, M., Aspenblad, U., Höög, A., Børresen‐Dale, A., & Auer, G. (1996) · Thyroid · doi:10.1089/thy.1996.6.1 · Cited by 71
Poulaki, V., Mitsiades, C. S., Kotoula, V., Tseleni-Balafouta, S., Ashkenazi, A., Koutras, D. A., & Mitsiades, N. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64220-4 · Cited by 69
Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788
Kim, S., Schiff, B. A., Yigitbasi, O. G., Doan, D., Jasser, S. A., Bekele, B. N., Mandal, M., & Myers, J. N. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0293 · Cited by 68
Nobuhara, Y., Onoda, N., Yamashita, Y., Yamasaki, M., Ogisawa, K., Takashima, T., Ishikawa, T., & Hirakawa, K. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602461 · Cited by 67
Motti, M. L., Califano, D., Baldassarre, G., Celetti, A., Merolla, F., Forzati, F., Napolitano, M., Tavernise, B., Fusco, A., & Viglietto, G. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi050 · Cited by 66
MicroRNAs as therapeutic targets in human diseases
Jeyaseelan, K., Herath, W. B., & Armugam, A. (2007) · Expert opinion on therapeutic targets · doi:10.1517/14728222.11.8.1119 · Cited by 65
Antonelli, A., Ferrari, S. M., Fallahi, P., Berti, P., Materazzi, G., Marchetti, I., Ugolini, C., Basolo, F., Miccoli, P., & Ferrannini, E. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0190 · Cited by 63
Kurihara, T., Ikeda, S., Ishizaki, Y., Fujimori, M., Tokumoto, N., Hirata, Y., Ozaki, S., Okajima, M., Sugino, K., & Asahara, T. (2004) · Thyroid · doi:10.1089/thy.2004.14.1020 · Cited by 62
Portella, G., Scala, S., Vitagliano, D., Vecchio, G., & Fusco, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8529 · Cited by 61
BRAFV600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
Takano, T., Ito, Y., Hirokawa, M., Yoshida, H., & Miyauchi, A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603764 · Cited by 60
Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines
Arlot‐Bonnemains, Y., Baldini, E., Martin, B., Delcros, J., Toller, M., Curcio, F., Ambesi‐Impiombato, F. S., D'Armiento, M., & Ulisse, S. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0021 · Cited by 60
Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma
Lee, J.-J., Au, A. Y. M., Foukakis, T., Barbaro, M., Kiss, N., Clifton-Bligh, R. J., Staaf, J., Borg, Å., Delbridge, L., Robinson, B. G., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0018 · Cited by 59
Increased Expression of Focal Adhesion Kinase in Thyroid Cancer: Immunohistochemical Study
Kim, S. J., Park, J., Yoon, J. S., Mok, J., Kim, Y. J., Park, H. K., Kim, C., Byun, D. W., Lee, Y. J., Jin, S. Y., et al. (2004) · Journal of Korean Medical Science · doi:10.3346/jkms.2004.19.5.710 · Cited by 57
Targeting BRAFV600E in thyroid carcinoma: therapeutic implications
Mitsiades, C. S., Negri, J. M., McMullan, C. J., McMillin, D. W., Sozopoulos, E., Fanourakis, G., Voutsinas, G. E., Tseleni‐Balafouta, S., Poulaki, V., Batt, D. B., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0449 · Cited by 57
Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells
Kurebayashi, J., Okubo, S., Yamamoto, Y., Ikeda, M., Tanaka, K., Otsuki, T., & Sonoo, H. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0185-x · Cited by 54
Fury, M. G., Solit, D. B., Su, Y. B., Rosen, N. X., Sirotnak, F. M., Smith, R. P., Azzoli, C. G., Gomez, J. E., Miller, V. A., Kris, M. G., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0286-6 · Cited by 53
Targeting IAP (Inhibitor of Apoptosis) Proteins for Therapeutic Intervention in Tumors
Vucic, D. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908783769373 · Cited by 52
Perspectives and Limitations of Microarray-Based Gene Expression Profiling of Thyroid Tumors
Eszlinger, M., Krohn, K., Kukulska, A., Jarząb, B., & Paschke, R. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0047 · Cited by 52
Husmark, J., Heldin, N., & Nilsson, M. (1999) · International Journal of Cancer · Cited by 52
Mizutani, K., Onda, M., Asaka, S., Akaishi, J., Miyamoto, S., Yoshida, A., Nagahama, M., Ito, K., & Emi, M. (2005) · Cancer · doi:10.1002/cncr.20988 · Cited by 52
Molecular Cytogenetic Profiles of Novel and Established Human Anaplastic Thyroid Carcinoma Models
Lee, J.-J., Foukakis, T., Hashemi, J., Grimelius, L., Heldin, N., Wallin, G., Rudduck, C., Lui, W., Höög, A., & Larsson, C. (2007) · Thyroid · doi:10.1089/thy.2006.0246 · Cited by 51
Climent, J., García, J. L., Mao, J., Arsuaga, J., & Pérez‐Losada, J. (2007) · Biochemistry and Cell Biology · doi:10.1139/o07-072 · Cited by 48
Veltman, J. A., & Vries, B. B. A. D. (2006) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.060131 · Cited by 47
Up-regulation of transcriptional factor E2F1 in papillary and anaplastic thyroid cancers
Onda, M., Nagai, H., Yoshida, A., Miyamoto, S., Asaka, S., Akaishi, J., Takatsu, K., Nagahama, M., Ito, K., Shimizu, K., et al. (2004) · Journal of Human Genetics · doi:10.1007/s10038-004-0146-3 · Cited by 46
Pushkarev, V. M., Starenki, D., Saenko, V., Namba, H., Kurebayashi, J., Tronko, M. D., & Yamashita, S. (2004) · Endocrinology · doi:10.1210/en.2004-0127 · Cited by 46
Rodrigues, R., Roque, L., Krug, T., & Leite, V. A. P. H. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603578 · Cited by 45
RbAp48 is a Target of Nuclear Factor-κB Activity in Thyroid Cancer
Pacifico, F., Paolillo, M., Chiappetta, G., Crescenzi, E., Arena, S., Scaloni, A., Monaco, M., Vascotto, C., Tell, G., Formisano, S., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2199 · Cited by 44
Epidermal Growth Factor Receptor as a Novel Therapeutic Target in Anaplastic Thyroid Carcinomas
Ensinger, C., Spizzo, G., Moser, P. L., Tschörner, I., Prommegger, R., Gabriel, M., Mikuz, G., & Schmid, K. W. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1329.009 · Cited by 44
Starenki, D., Namba, H., Saenko, V., Ohtsuru, A., & Yamashita, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031216 · Cited by 43
Schmutzler, C., Hoang-Vu, C., Ruger, B., & Köhrle, J. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500547 · Cited by 42
Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma
Voigt, W., Kegel, T., Weiss, M., Mueller, T., Simon, H., & Schmoll, H. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-005-0673-0 · Cited by 41
Hayashi, N., Nakamori, S., Hiraoka, N., Tsujie, M., Xu, X., Takano, T., Amino, N., Sakon, M., & Monden, M. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.1.89 · Cited by 39
Meng, Z., Mitsutake, N., Nakashima, M., Starenki, D., Matsuse, M., Takakura, S., Namba, H., Saenko, V., Umezawa, K., Ohtsuru, A., et al. (2008) · Endocrinology · doi:10.1210/en.2008-0279 · Cited by 38
Mineva, I., Gärtner, W., Hauser, P., Kainz, A., Löffler, M. G., Wolf, G., Oberbauer, R. W., WEISSEL, M., & Wagner, L. (2005) · Cell Stress and Chaperones · doi:10.1379/csc-107r.1 · Cited by 36
Thyroid Transcription Factor-2 Gene Expression in Benign and Malignant Thyroid Lesions
Sequeira, M., Morgan, J. M., Führer, D., Wheeler, M. H., Jasani, B., & Ludgate, M. (2001) · Thyroid · doi:10.1089/105072501753271662 · Cited by 35
Kebebew, E., Peng, M., TRESELER, P. A., Clark, O. H., Duh, Q., Ginzinger, D. G., & Miner, R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1234 · Cited by 34
Miyake, N., Maeta, H., Horie, S., Kitamura, Y., Nanba, E., Kobayashi, K., & Terada, T. (2001) · Pathology International · doi:10.1046/j.1440-1827.2001.01269.x · Cited by 33
Balthasar, S., Bergelin, N., Löf, C., Vainio, M., Andersson, S., & Törnquist, K. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0253 · Cited by 32
Plitidepsin Has a Cytostatic Effect in Human Undifferentiated (Anaplastic) Thyroid Carcinoma
Bravo, S. B., García-Rendueles, M. E. R., Seoane, R., Dosil, V., Cameselle‐Teijeiro, J., Lázaro, L. L., Zalvide, J. B., Barreiro, F. J. J., Pombo, C. M., & Álvarez, C. V. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0455 · Cited by 30
Microarray tools for deciphering complex diseases
Mehrian‐Shai, R. (2006) · Frontiers in bioscience · doi:10.2741/1892 · Cited by 25
Schott, M. (2009) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(09)79274-1 · Cited by 23
Abbosh, P. H., Li, X., Li, L., Gardner, T. A., Kao, C. H., & Nephew, K. P. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701024 · Cited by 21
Clinical Impact of Molecular Analysis on Thyroid Cancer Management
Wreesmann, V. B., & Singh, B. (2008) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.10.013 · Cited by 19
Bulgin, D. V., Podtcheko, A., Takakura, S., Mitsutake, N., Namba, H., Saenko, V., Ohtsuru, A., Rogounovitch, T., Palona, I., & Yamashita, S. (2006) · Thyroid · doi:10.1089/thy.2006.16.217 · Cited by 14
Xu, J., Filetti, S., & Hershman, J. M. (2008) · Thyroid · doi:10.1089/thy.2007.0312 · Cited by 5
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Guidelines for the management of thyroid cancer
Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R. M., Gerrard BA, G., Gilbert, J., Harrison, B., Johnson, S. J., Giles, T. E., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12515 · Cited by 1,372
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85271 · Cited by 1,284
Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,027
Biologic and Clinical Perspectives on Thyroid Cancer
Fagin, J. A., & Wells, S. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1501993 · Cited by 990
Metadata
- Authors
- Smallridge, R. C., Marlow, L. A., & Copland, J. A.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2009-03
- Volume
- 16
- Issue
- 1
- Pages
- 17-44
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2108668400
- Cited by
- 390
- References
- 175
- FWCI
- 14.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.